Eisai announced that the FDA has approved Aciphex Sprinkle (rabeprazole sodium) Delayed-Release Capsules for the treatment of gastroesophageal reflux disease (GERD) in children 1–11 years of age for ...
Eisai announced that Aciphex Sprinkle (rabeprazole sodium) Delayed-Release Capsules are now available for the treatment of gastroesophageal reflux disease (GERD) in children 1–11 years old for up to ...
March 13, 2007 — The US Food and Drug Administration (FDA) has approved first-time generic formulations for rabeprazole sodium 20-mg delayed-release tablets and ranitidine HCl 15-mg/mL oral ...
WOODCLIFF LAKE, N.J., Nov. 30, 2012 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review Eisai's New Drug Application (NDA) for ...
The US Food and Drug Administration (FDA) has approved the first generic versions of Aciphex (rabeprazole sodium; Eisai) delayed-release tablets for the treatment of gastroesophageal reflux disease ...
HealthDay News — The FDA has approved the first generic versions of the gastroesophageal reflux disease (GERD) drug Aciphex (rabeprazole sodium) for people aged 12 and older, the agency has announced.
Japan’s Eisai says that US regulators have granted a priority review for a new application of the firm’s proton pump inhibitor Aciphex. Japan’s Eisai says that US regulators have granted a priority ...
TOKYO A United States appeals court ruled Monday to block generic competition to Tokyo-based Eisai’s stomach ulcer drug Aciphex. The U.S. Court of Appeals for the Federal Circuit ruled against Teva ...
(HealthDay)—The first generic versions of the anti-GERD drug Aciphex (rabeprazole sodium) have been approved by the U.S. Food and Drug Administration for people aged 12 and older, the agency said ...
When discussing AcipHex online, consumers are frequently discussing being prescribed the medication after serious GERD issues that ended up in hospitalization. Similar to AcipHex, consumers talking ...
NEW YORK, May 11 (Reuters) - A U.S. court on Friday upheld drug companies seeking to sell cheap versions of the medicine. The court decision was a major victory for Japan-based Eisai, which derives ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results